UthPeak®: Validated for Safety and Efficacy
UthPeak® stands alone as the only NMNH (Reduced NMN) supplement on the market with clinically validated safety and efficacy. Our dedication to consumer well-being has led us to conduct exhaustive toxicology tests across various matrices. These tests underscore its potential to support anti-aging, anti-fatigue, improve sleep quality, enhance brain function and promote cardiovascular health. Such clinical trials are pivotal in building consumer confidence, ensuring that UthPeak® meets the highest standards of safety and efficacy. Our transparent approach in validating UthPeak®'s safety underscores our commitment to not only meet but exceed industry standards.
Aim of Clinical Trials
PreClinical Studies
The preclinical trials for UthPeak® are designed to lay a solid foundation for clinical trials. The aim is to evaluate the compound's safety profile, such as its non-mutagenic nature and absence of acute oral toxicity, as well as its effect on chromosomal stability. The outcomes of these tests are crucial; they will directly influence the design and focus of subsequent clinical tests, ensuring a scientifically sound basis for further exploration of UthPeak®'s health benefits.
Pre-Clinical Studies
Jun.14, 2023
No mutagenicity
Bacterial reverse mutation test (Ames test)
Jun.15, 2023
No acute oral toxicity
Acute oral toxicity in rat
Jul. 25, 2023
Non-cytotoxic & Non-clastogenic
In vivo Chromosomal Aberration
test in Mouse
Aug. 31, 2023
Non-cytotoxic & Non-clastogenic
Bone Marrow In Vitro Mammalian
Cell Micronucleus test in CHO K1 cel1 line
Nov. 30, 2023
No toxcitiy, NOALE ≥ 1000mg/kg BW
Repeated dose 90 days oral
toxicity study in rats
UthPeak® Clinical Trial Timeline
The forthcoming UthPeak® clinical trials will concentrate on assessing NMNH’s potential in enhancing consumer-centric well-being factors, such as cardioprotection, energy enhancement, and liver protection.
2023
Toxicology Testing Completed
​
In 2023, UthPeak® completed a series of comprehensive toxicology tests. These tests were critical in assessing the safety of NMNH, examining aspects such as its non-mutagenicity, lack of acute oral toxicity, and potential for causing chromosomal aberrations, thereby setting a safe groundwork for human trials.
​
2024
Phase I - Clinical Trial Completed
​
The Phase I clinical trial will primarily focus on determining the safety and tolerability of UthPeak® in human subjects. This phase is crucial for establishing dosage ranges and identifying any potential side effects of this NAD+ booster, setting the stage for more extensive testing in Phase II.
2025
Phase II - Clinical Trial
​
In the Phase II clinical trial set for 2025, the focus will shift towards evaluating the efficacy of UthPeak®. This phase will test the NMNH supplement's effectiveness in improving well-being factors like cardioprotection, energy enhancement, and liver protection in a larger group of participants, providing deeper insights into its health benefits.
Future Directions and Ongoing Research
The insights gained from UthPeak®'s ongoing and completed clinical studies are instrumental in shaping future research directions. They offer valuable data that not only reinforce the safety and efficacy of NMNH but also open new avenues for its application in health and wellness. Further studies are planned to explore these possibilities, continually advancing our understanding of NMNH's potential in human health.